Sistemic hires more staff

Moves to larger premises that will become new global hq

Sistemic, a Glasgow, Scotland-based developer of microRNA technologies, has added scientific and bioinformatic staff, and is moving to larger premises near Glasgow, which will also form the company’s new global headquarters.

The company says this will enable it to fulfil current contracts more rapidly, while providing further capacity for newly acquired and future contracts. It will also support the expansion of its key internal r&d programmes in drug toxicology and stem cell characterisation.

The expansion programme will also see the company grow its US commercial operations by developing its Boston location and opening an office in California.

David Mallinson, who previously worked for Merck Sharpe Dohme (MSD), has joined Sistemic as a senior scientist and will lead new projects at the expanded facility.

Max Bylesjo, previously at Almac Group, has joined as senior bioinformatician and will focus on developing Sistemic’s data processing technology.

The new Sistemic headquarters will dedicate 60% of its space to laboratory facilities, equipped with state-of-the-art technology, and 40% as new commercial areas.

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic announces companion biomarker programme

Extends miRNA drug discovery toolkit
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Subscribe now